Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High-resolution colonic manometry interobserver analysis trial.

Neurogastroenterology and motility·2021

Same author

Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide.

Journal of gastrointestinal and liver diseases : JGLD·2020

Same author

Faecal microbiota transplantation for <i>Clostridioides difficile</i> infection: Four years' experience of the Netherlands Donor Feces Bank.

United European gastroenterology journal·2020

Same author

Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed.

United European gastroenterology journal·2020

Same author

Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug.

United European gastroenterology journal·2019

Same author

Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.

The Journal of pathology·2019

Search research articles

Related Experiment Video

Updated: May 29, 2026

Characteristics of Precipitation-formed Polyethylene Glycol Microgels Are Controlled by Molecular Weight of Reactants

Characteristics of Precipitation-formed Polyethylene Glycol Microgels Are Controlled by Molecular Weight of Reactants

Published on: December 23, 2013

Differences in taste between three polyethylene glycol preparations: a randomized double-blind study.

Tze J Lam¹, Chris Jj Mulder, Richelle Jf Felt-Bersma

¹Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands.

Patient Preference and Adherence

|September 28, 2011

Summary

Laxtra Orange(®) was the preferred polyethylene glycol 3350 preparation among study participants due to its superior taste. This finding suggests potential improvements in patient adherence for chronic constipation management.

Keywords:

constipation laxative laxtra macrogol medication adherence molaxole movicol polyethylene glycol

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Taste Exam: A Brief and Validated Test

Taste Exam: A Brief and Validated Test

Published on: August 17, 2018

Related Experiment Videos

Last Updated: May 29, 2026

Characteristics of Precipitation-formed Polyethylene Glycol Microgels Are Controlled by Molecular Weight of Reactants

Characteristics of Precipitation-formed Polyethylene Glycol Microgels Are Controlled by Molecular Weight of Reactants

Published on: December 23, 2013

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Taste Exam: A Brief and Validated Test

Taste Exam: A Brief and Validated Test

Published on: August 17, 2018

Area of Science:

Gastroenterology
Pharmacology

Background:

Chronic constipation necessitates long-term laxative therapy.
Patient preference and acceptance data for polyethylene glycol (PEG) preparations are limited.
Taste significantly influences adherence to long-term treatments.

Purpose of the Study:

To compare patient preference among three polyethylene glycol 3350 formulations: Molaxole(®), Movicol(®), and Laxtra Orange(®).
To assess the palatability of different PEG 3350 preparations, a key factor for treatment adherence.

Main Methods:

A randomized, cross-over, double-blind study involving 100 volunteers.
Volunteers rated preparation taste on a five-point hedonic scale.
Participants selected their most preferred preparation.

Main Results:

Laxtra Orange(®) received the highest mean hedonic taste score (3.12), significantly outperforming Molaxole(®) (2.76) and Movicol(®) (2.81).
Laxtra Orange(®) was the most preferred preparation for 56% of volunteers, compared to 25% for Movicol(®) and 19% for Molaxole(®).
No significant differences in preference were observed based on age or gender, and the order of testing did not influence results.

Conclusions:

Laxtra Orange(®) demonstrated superior palatability compared to Molaxole(®) and Movicol(®).
The enhanced taste profile of Laxtra Orange(®) may positively impact patient adherence in managing chronic constipation.